AlphAIAlphAI — Financial news for AI agents
medcitynews.comOCT 282 min read$LLY

Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial

Eli Lilly's experimental drug retatrutide showed greater improvement in type 2 diabetes measures than Novo's Ozempic in a Phase 3 trial, reducing A1C levels by 2.2 points vs. 1.8 for Ozempic. Retatrutide also led to more weight loss and better cardiovascular metrics but had higher side effects. Lilly plans to present detailed data later. Analysts see potential for premium pricing and $15B in 2032 sales if approved.

Original reporting
medcitynews.com
Published Oct 28, 2026, 6:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 6:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial — source image
Source · medcitynews.com
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The data suggest a strong competitive advantage for Lilly, likely leading to analyst upgrades and price appreciation.

02

Market read

First disclosure of a potentially blockbuster diabetes/obesity drug could shift market expectations for the sector.

03

What to watch

Regulatory timeline, reimbursement negotiations, and competition from tirzepatide may affect commercialization speed.

Relevance 8/10Novelty 8/10Timing: upon data release

Background

The article reports first‑time Phase 3 results for retatrutide, a triple‑receptor peptide, comparing it directly to Ozempic.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly's Phase 3 trial of retatrutide showed superior A1C and weight loss versus Ozempic, a first public disclosure of the data.

Expected impact

likely upward pressure as market prices in potential premium pricing and market share gain.

Evidence & confidence

The data are novel, show clear efficacy advantage, and support a multi‑billion dollar revenue outlook, prompting re‑rating by analysts.

Market effects

Sector

Strengthens the GLP‑1/GIP/glucagon class, pressuring peers like Novo Nordisk and other obesity‑diabetes players.

Regional

U.S. biotech sector may see modest gains as investors reassess pipeline valuations.

Global

Potentially reshapes global diabetes/obesity drug market dynamics.

Counterpoint

What could challenge this read

Higher gastrointestinal side‑effects and discontinuation rates could limit adoption and dampen price impact.

Key entities

  • Company
    Eli Lilly

    Pharmaceutical developer of retatrutide.

  • Company
    Novo Nordisk

    Maker of Ozempic, used as comparator.

Read at source← All news

StoryEli Lilly’s retatrutide cuts A1C and weight far more than Ozempic in Phase 3 head‑to‑head trial

Also covered by

6 outlets

Related articles

OCT 28
$LLYMedAI 8/10

Lilly’s retatrutide beats Ozempic in head-to-head trial

Eli Lilly's retatrutide outperformed Novo Nordisk's Ozempic in a Phase III trial, achieving 19.5-20.9% weight loss vs. Ozempic's 9.4%, and greater A1C reduction. Retatrutide also improved cardiovascular risk factors. Lilly and Novo are competitors in the obesity and type 2 diabetes market, with ongoing legal and market disputes.

finance.yahoo.com2 min
OCT 28
$LLYMed

Eli Lilly Stocks Rise After Retatrutide's Head-to-Head Trial Results

Eli Lilly's shares rose 1.21% to $1,297.37 after its experimental drug retatrutide showed superior weight loss and blood sugar control in a head-to-head trial with Ozempic. The 80-week trial in type 2 diabetes patients showed retatrutide patients lost 47.4 pounds on average, compared to 20.9 pounds with Ozempic. However, more retatrutide patients discontinued treatment due to adverse events. Lilly's market value is $1.22 trillion with a P/E ratio of 44.08, indicating high investor expectations.

finance.yahoo.com2 min
OCT 28
$LLYMed

Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

Eli Lilly's retatrutide outperformed Novo Nordisk's Ozempic in a Phase 3 trial, showing greater blood sugar reduction and weight loss. The highest dose of retatrutide reduced blood sugar by 2.2 percentage points, compared to Ozempic's 1.8 points. Retatrutide also demonstrated significant weight loss, with the highest dose resulting in a 21% reduction, but had higher discontinuation rates due to side effects.

finance.yahoo.com2 min
OCT 28
$LLYHigh

Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial

Eli Lilly's retatrutide showed greater reductions in HbA1c and weight loss compared to Novo Nordisk's semaglutide in a phase 3 trial. Retatrutide lowered HbA1c by 2.2 points and achieved 19.5-20.9% weight loss, while semaglutide achieved 1.8 points and 9.4% weight loss. Adverse events led to higher discontinuation rates with retatrutide.

ajmc.com3 min
OCT 28
$NVOMedAI 8/10

Novo Nordisk, Eli Lilly, Pfizer, Roche, Amgen, and Viking Therapeutics are developing new weight-loss drugs

Novo Nordisk, Eli Lilly, Pfizer, Roche, Amgen, and Viking Therapeutics are developing new weight-loss drugs. Novo Nordisk is working on CagriSema and amycretin, while Eli Lilly has Foundayo, retatrutide, and EloraTZP. Roche's enicepatide showed 15.5% weight loss in mid-stage trials, with late-stage tests planned for 2027. Amgen's MariTide is in late-stage trials for obesity and related conditions.

qz.com2 min